Athyrium raises $2B for debt/equity fund; Amgen teams with Carmot on Parkinson's; Neuralstem soars on failed study(?)
→ New York-based Athyrium Capital Management has closed on a new $2 billion healthcare fund to support some expanded work in the biopharma field, among others. Athyrium provides cash as debt as well as equity, with a record for backing a number of loans to companies like Relypsa, Recro and Progenity. And they’ll be backing companies around the world to the tune of $20 million to $300 million out of the new fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
